A 24 Month Phase 2A Open Label Safety Study of Fovista (Anti-PDGF-BB Pegylated Aptamer) Regiment Administered in Combination With Avastin, Eylea, or Lucentis) During the Induction and Maintenance Phase of Therapy
Phase of Trial: Phase II
Latest Information Update: 11 Jul 2019
Price : $35 *
At a glance
- Drugs Pegpleranib (Primary) ; Vascular endothelial growth factors inhibitors
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors IVERIC bio
- 31 Aug 2018 Biomarkers information updated
- 19 Dec 2016 Status changed from active, no longer recruiting to discontinued.
- 05 Aug 2015 According to an Ophthotech media release, interim data from this trial is expected by the end of 2015.